Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Gets Price Target Boost from Truist Financial

Key Points

• Truist Financial raised Regeneron’s price target from $780 to $982 and maintained a “buy” rating. Other analysts also increased their targets, with the consensus rating at “Moderate Buy” and the average target at $890.97.
• Regeneron reported strong quarterly results, with earnings of $20.07 per share versus the $16.51 consensus and revenue of $5.12 billion, up 36.3% year over year.
• Shares traded near their 52-week high at $968.29, while institutional investors owned 83.31% of the company; insiders sold approximately $6.5 million of stock over the past three months.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its target price lifted by equities research analysts at Truist Financial from $780.00 to $982.00 in a research report issued to clients and investors on Monday, Benzinga reports. The firm currently has a "buy" rating on the biopharmaceutical company's stock. Truist Financial's price target would suggest a potential upside of 1.42% from the stock's current price.

A number of other equities research analysts also recently weighed in on REGN. Canaccord Genuity Group upped their target price on Regeneron Pharmaceuticals from $875.00 to $922.00 and gave the stock a "buy" rating in a research report on Wednesday, October 28th. Guggenheim lifted their price target on Regeneron Pharmaceuticals from $1,030.00 to $1,100.00 and gave the company a "buy" rating in a research report on Monday. Cantor Fitzgerald boosted their price objective on Regeneron Pharmaceuticals from $795.00 to $980.00 and gave the stock an "overweight" rating in a research note on Monday. Wall Street Zen raised Regeneron Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Sunday, September 20th. Finally, Robert W. Baird upped their price objective on Regeneron Pharmaceuticals from $761.00 to $875.00 and gave the company a "neutral" rating in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $890.97.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN traded up $40.40 during midday trading on Monday, reaching $968.29. 637,215 shares of the company traded hands, compared to its average volume of 821,362. Regeneron Pharmaceuticals has a 52 week low of $591.52 and a 52 week high of $972.06. The stock has a 50-day moving average price of $793.30 and a 200 day moving average price of $738.05. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.06 and a quick ratio of 3.66. The company has a market cap of $99.70 billion, a price-to-earnings ratio of 21.35, a PEG ratio of 1.57 and a beta of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, topping the consensus estimate of $16.51 by $3.56. The business had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $4.58 billion. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The company's quarterly revenue was up 36.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $11.83 earnings per share. Sell-side analysts anticipate that Regeneron Pharmaceuticals will post 49.10 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Marion Mccourt sold 1,131 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, September 3rd. The stock was sold at an average price of $857.39, for a total value of $969,708.09. Following the transaction, the executive vice president owned 12,003 shares of the company's stock, valued at approximately $10,291,252.17. This trade represents a 8.61% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andrew J. Murphy sold 4,147 shares of the business's stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total value of $3,204,386.90. Following the sale, the insider owned 47,833 shares in the company, valued at approximately $36,960,559.10. The trade was a 7.98% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 8,093 shares of company stock valued at $6,506,845. 6.97% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the business. Western Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth approximately $26,000. Armstrong Advisory Group Inc. boosted its holdings in shares of Regeneron Pharmaceuticals by 466.7% during the third quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 28 shares during the period. Mowery & Schoenfeld Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth approximately $29,000. Trust Co. of Vermont purchased a new position in Regeneron Pharmaceuticals during the second quarter valued at approximately $29,000. Finally, Fiduciary Financial Advisors purchased a new position in Regeneron Pharmaceuticals during the second quarter valued at approximately $29,000. Hedge funds and other institutional investors own 83.31% of the company's stock.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Strong Q3 results: Regeneron reported earnings of $20.07 per share, well above the $16.51 analyst consensus, while revenue rose 36% year over year to approximately $5.1 billion. Earnings growth of about 70%, strong Dupixent sales and a larger Sanofi profit share are reinforcing investor confidence. These Analysts Raise Their Forecasts On Regeneron Pharmaceuticals After Upbeat Q3 Results
• Positive Sentiment: Analysts raised targets: Guggenheim lifted its target to $1,100 and initiated a “buy” view, while JPMorgan raised its target to $1,050 with an “overweight” rating. Bank of America increased its target to $1,030 and kept a “buy” rating; broader analyst forecasts reportedly reach as high as $1,175. Regeneron Pharmaceuticals Analyst Forecasts
• Positive Sentiment: Pipeline and commercial momentum: Investors are also responding to the company’s deep pipeline, encouraging Libtayo data in high-risk skin cancer and an expanded BARDA supply agreement for an Ebola treatment. Why Regeneron Shares Are In Focus After Strong Earnings
• Positive Sentiment: Shareholder returns: Regeneron declared a quarterly dividend of $0.94 per share, payable December 3, and continues repurchases under its buyback program.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.